title: Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
authors.affiliation: St Francis Cancer Treatment Center, Grand Island, NE mcopur@sfmc-gi.org.
authors.forename: Mehmet S
authors.initials: MS
authors.lastname: Copur
authors.affiliation: St Francis Cancer Treatment Center, Grand Island, NE.
authors.forename: Dron
authors.initials: D
authors.lastname: Gauchan
authors.affiliation: St Francis Cancer Treatment Center, Grand Island, NE.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Brussow
authors.affiliation: St Francis Cancer Treatment Center, Grand Island, NE.
authors.forename: Douglas
authors.initials: D
authors.lastname: Clark
authors.affiliation: St Francis Cancer Treatment Center, Grand Island, NE.
authors.forename: Ryan
authors.initials: R
authors.lastname: Ramaekers
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D005260:Female; D018095:Germ-Line Mutation; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines